{"groups":[{"description":"Patients receive defactinib PO 400 mg BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Defactinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Never Start Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Mutation Status Not Confirmed"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other Complicating Disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients whose tumors harbored an inactivating NF2 mutation on next-generation sequencing were assigned to sub-protocol U. The mutation status was determined by an NCI-MATCH approved laboratory for 8 patients in this arm, these cases had to be confirmed to be used in primary analysis.","recruitmentDetails":"Subprotocol U was activated on August 12, 2015. Thirty-five patients were enrolled on EAY131-U between November 19, 2015, and November 8, 2017. Twenty-seven patients were enrolled on the basis of the results from the NCI-MATCH assay and 8 on the basis of the outside assay results."}